Tumor-reactive murine CD8 αβ T cells expanded ex vivo using IL-15 [44, 45] or IL-7/IL-15 [46] mediate increased tumor immunity in vivo as compared to cells grown in IL-2. The gene discussed is IL15; the disease is neoplasm.